StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
Genocea Biosciences Company Profile
See Also
- Five stocks we like better than Genocea Biosciences
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 4/29 – 5/3
- What Are Dividend Contenders? Investing in Dividend Contenders
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The How And Why of Investing in Oil Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.